3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Testicular Neoplasms
5
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
4
Testicular Germ Cell Tumor
4
Seminoma
3
Ovarian Neoplasms
3
Endodermal Sinus Tumor
3
Central Nervous System Neoplasms
3
Urethral Neoplasms
2
Teratoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Embryonal
2
Wilms Tumor
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pancreatic Neoplasms
1
Pain
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Melanoma
1
Kidney Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Dysgerminoma
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
4
Etoposide
3
pembrolizumab
2
fludarabine
2
etoposide phosphate
2
Sirolimus
2
Paclitaxel
2
Mesna
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Cisplatin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
tremelimumab
1
ripretinib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
guadecitabine
1
fosaprepitant
1
fludarabine phosphate
1
durvalumab
1
bintrafusp alfa protein, human
1
avelumab
1
Vorinostat
1
Ursodeoxycholic Acid
1
Topotecan
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
pegfilgrastim
×
Genitourinary
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled